


## AMENDMENTS TO THE CLAIMS


This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-107 (Canceled)

108. (Currently amended) A compound which contains a determinant having the structure:




wherein the compound is bound to a suitable carrier protein or ~~lipid~~ peptide, said compound being bound either directly or by a cross-linker selected from the group consisting of a succinimide and an ~~M<sub>2</sub> linker~~ a linker having the structure:




~~with the proviso that when R is a ceramide moiety, the set of indices (r, m, n) is not (1, 0, 1).~~

110. (Currently amended) A compound having the structure:




wherein  $r$ ,  $m$ , and  $n$  are independently 0, 1, 2 or 3;

$R$  is H, substituted or unsubstituted allyl, an amino acyl moiety, or a moiety having the structure:



wherein the linker is  $-(CH_2)_s-CH_2-$  or  $-(CH_2)_s-CH=$  where  $s$  is an integer between 0 and 8;

the crosslinker is selected from the group consisting of a succinimide and an  $M_2$  linker a linker having the structure:




$q$  is 0 or 1; and

the carrier is a ~~protein, peptide or lipid~~, protein or peptide, and is optionally chemically modified prior to conjugation with the linker when  $q$  is 0, or with the crosslinker when  ~~$q$  is 1~~;  $q$  is 1.

with the proviso that when R is a ceramide moiety, the set of indices (r, m, n) is not (1, 0, 4).

111. (Previously presented) The compound of claim 108 or 110 wherein the protein is bovine serum albumin, polylysine, or keyhole limpet hemocyanin.


112. (Withdrawn) A compound having the structure:




wherein r is 0, 1, 2, 3, or 4.

113. (Withdrawn) The compound of claim 112 wherein r is 1.

114. (Currently amended) A composition comprising a compound which contains a determinant having the structure:




wherein the compound is bound to a suitable carrier protein or ~~lipid~~ peptide, said compound being bound either directly or by a cross-linker selected from the group consisting of a succinimide and ~~an M<sub>2</sub>-linker~~ a linker having the structure:



and an immunological adjuvant and/or a pharmaceutically acceptable ~~carrier~~; carrier.  
~~with the proviso that when R is a ceramide moiety, the set of indices (r, m, n) is not (1, 0, 1).~~


---

116. (Currently amended) A composition comprising a compound having the structure:




wherein r, m, and n are independently 0, 1, 2 or 3;

R is H, substituted or unsubstituted alkyl, aryl or allyl, an amino acyl moiety, or a moiety having the structure:



wherein the linker is  $-(CH_2)_s-CH_2-$  or  $-(CH_2)_s-CH=$  where s is an integer between 0 and 8;

the crosslinker is selected from the group consisting of a succinimide and an  $M_2$  linker a linker having the structure:



q is 0 or 1; and

the carrier is a ~~protein, peptide or lipid~~, protein or peptide and is optionally chemically modified prior to conjugation with the linker when q is 0, or with the crosslinker when q is 1;

and an immunological adjuvant and/or a pharmaceutically acceptable ~~carrier~~;

carrier.

~~with the proviso that when R is a ceramide moiety, the set of indices (r, m, n) is not (1, 0, 1).~~

117. (Previously presented) The composition of claim 114 or 116 wherein the protein is bovine serum albumin, polylysine, or keyhole limpet hemocyanin.
118. (Previously presented) The composition of claim 114 or 116 wherein the immunological adjuvant is bacteria or liposomes.
119. (Previously presented) The composition of claim 118 wherein the adjuvant is *Salmonella minnesota* cells, bacille Calmette-Guerin or QS21.